Recurrent COVID‐19 pneumonia in the course of chemotherapy: Consequence of a weakened immune system?
Michelangelo Luciani(Sapienza University of Rome), Luciano De Biase(Azienda Ospedaliera Sant'Andrea), P Lamberti(Sapienza University of Rome), Enrico Bentivegna(Azienda Ospedaliera Sant'Andrea), Flavia Del Porto, Giorgio Sesti(Magna Graecia University), Valerio Spuntarelli(Sapienza University of Rome), Giulio Cacioli, Paolo Martelletti(Unitelma Sapienza University)
Cited by 22
Related Papers
Safety issues with glucagon‐like peptide‐1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): <scp>D</scp> ata from randomized controlled trials
|Diabetes Obesity and Metabolism|2017|226
Review of methods for detecting glycemic disorders
|Diabetes Research and Clinical Practice|2020|193
3D Microfluidic model for evaluating immunotherapy efficacy by tracking dendritic cell behaviour toward tumor cells
|Scientific Reports|2017|176
Hallmarks of primary headache: part 1 – migraine
|The Journal of Headache and Pain|2024|169
Long COVID headache
|The Journal of Headache and Pain|2022|158